Avastin, one of the best-selling cancer drugs in the world, could be banned from the treatment of breast cancer after a Federal Drug Administration (FDA) panel found for the second time the drug was ...

– Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of ...

Amid growing controversy after several delays in making a decision, the Food and Drug Administration announced it would not approve of the use of the drug Avastin in the treatment of breast cancer.

At the European Society of Medical Oncology (ESMO) Congress 2024, updated efficacy and safety data from the randomised, controlled Phase III IMbrave050 clinical trial were presented on 13 September.

LOS ANGELES, May 20 (Reuters) - Colorectal cancer patients who continued treatment with Roche Holding AG's Avastin even after their cancer worsened lived longer than those who went off the drug, ...

Adding Imfinzi and Avastin to transarterial chemoembolization led to a 23% reduction in the risk of progression or death in patients with liver cancer. Patients with unresectable hepatocellular ...

The final overall survival results of the PAOLA-1/ENGOT-ov25 trial confirmed the drug combination as “one of the standards of care” for some populations of patients with ovarian cancer. Maintenance ...

The approval for Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for the treatment of women with stage III or stage IV epithelial ovarian, fallopian ...

Adding bevacizumab to the combination therapy of carboplatin and paclitaxel significantly improved progression-free survival (PFS) in patients with epithelial ovarian cancer (EOC) but not overall ...